FAQ

LCZ696 Intermediate is predominantly used in the pharmaceutical industry, particularly in the synthesis of LCZ696 (Entresto®), a medication for heart failure.

LCZ696, a dual-acting angiotensin receptor-neprilysin inhibitor (ARNI), combines sacubitril and valsartan to treat heart failure with reduced ejection fraction (HFrEF) and hypertension. Its intermediate is critical for the following reasons:

1. Drug Synthesis: LCZ696 Intermediate serves as a key precursor in the manufacturing process of LCZ696. Its purity and structural integrity directly influence the efficacy and safety of the final drug.
2. Research and Development: Pharmaceutical companies rely on this intermediate to explore dosage forms, formulations, and combination therapies, aiming to optimize LCZ696’s therapeutic potential.
3. Regulatory Compliance: Stringent quality standards for intermediates ensure the final drug meets regulatory requirements (e.g., FDA, EMA), making the intermediate a focal point in quality control.

While LCZ696 Intermediate may have niche applications in academic research (e.g., studying ARNI mechanisms) or specialty chemical synthesis, its primary and most impactful use remains in pharmaceutical manufacturing. This aligns with the global demand for heart failure treatments, underscoring the intermediate’s role in addressing a critical unmet medical need.